Abstract
Purpose: To assess the utility of contrast-enhanced agent detection imaging (ADI) in the assessment of the therapeutic response to percutaneous radiofrequency (RF) ablation in patients with hepatocellular carcinoma (HCC). Materials and methods: Ninety patients with a total of 97 nodular HCCs (mean, 2.1 ± 1.3 cm; range, 1.0-5.0 cm) treated with percutaneous RF ablation under the ultrasound guidance were evaluated with contrast-enhanced ADI after receiving an intravenous bolus injection of a microbubble contrast agent (SH U 508A). We obtained serial contrast-enhanced ADI images during the time period from 15 to 90 s after the initiation of the bolus contrast injection. All of the patients underwent a follow-up four-phase helical CT at 1 month after RF ablation, which was then repeated at 2-4 month intervals during a period of at least 12 months. The results of the contrast-enhanced ADI were compared with those of the follow-up CT in terms of the presence or absence of residual unablated tumor and local tumor progression in the treated lesions. Results: On contrast-enhanced ADI, technical success was obtained in 94 (97%) of the 97 HCCs, while residual unablated tumors were found in three HCCs (3%). Two of the three tumors that were suspicious (was not proven) for incomplete ablation were subjected to additional RF ablation. The remaining one enhancing lesion that was suspicious of a residual tumor on contrast-enhanced ADI was revealed to be reactive hyperemia at the 1-month follow-up CT. Therefore; the diagnostic concordance between the contrast-enhanced ADI and 1-month follow-up CT was 99%. Of the 94 ablated HCCs without residual tumors on both the contrast-enhanced ADI and 1-month follow-up CT after the initial RF ablation, five (5%) had CT findings of local tumor progression at a subsequent follow-up CT. Conclusion: Despite its limitations in predicting local tumor progression in the treated tumors, contrast-enhanced ADI is potentially useful for evaluating the early therapeutic effect of percutaneous RF ablation for HCCs.
| Original language | English |
|---|---|
| Pages (from-to) | 66-73 |
| Number of pages | 8 |
| Journal | European Journal of Radiology |
| Volume | 56 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2005 Oct 1 |
| Externally published | Yes |
Fingerprint
Keywords
- Agent detection imaging
- Computed tomography
- Contrast media
- Liver neoplasms
- Radiofrequency ablation
- Ultrasonography
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma : Utility of contrast-enhanced agent detection imaging. / Kim, Chan Kyo; Choi, Dongil; Lim, Hyo K.; Seung, Hoon Kim; Won, Jae Lee; Kim, Min Ju; Ji, Yeon Lee; Yong, Hwan Jeon; Lee, Jongmee; Soon, Jin Lee; Jae, Hoon Lim.
In: European Journal of Radiology, Vol. 56, No. 1, 01.10.2005, p. 66-73.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma
T2 - Utility of contrast-enhanced agent detection imaging
AU - Kim, Chan Kyo
AU - Choi, Dongil
AU - Lim, Hyo K.
AU - Seung, Hoon Kim
AU - Won, Jae Lee
AU - Kim, Min Ju
AU - Ji, Yeon Lee
AU - Yong, Hwan Jeon
AU - Lee, Jongmee
AU - Soon, Jin Lee
AU - Jae, Hoon Lim
PY - 2005/10/1
Y1 - 2005/10/1
N2 - Purpose: To assess the utility of contrast-enhanced agent detection imaging (ADI) in the assessment of the therapeutic response to percutaneous radiofrequency (RF) ablation in patients with hepatocellular carcinoma (HCC). Materials and methods: Ninety patients with a total of 97 nodular HCCs (mean, 2.1 ± 1.3 cm; range, 1.0-5.0 cm) treated with percutaneous RF ablation under the ultrasound guidance were evaluated with contrast-enhanced ADI after receiving an intravenous bolus injection of a microbubble contrast agent (SH U 508A). We obtained serial contrast-enhanced ADI images during the time period from 15 to 90 s after the initiation of the bolus contrast injection. All of the patients underwent a follow-up four-phase helical CT at 1 month after RF ablation, which was then repeated at 2-4 month intervals during a period of at least 12 months. The results of the contrast-enhanced ADI were compared with those of the follow-up CT in terms of the presence or absence of residual unablated tumor and local tumor progression in the treated lesions. Results: On contrast-enhanced ADI, technical success was obtained in 94 (97%) of the 97 HCCs, while residual unablated tumors were found in three HCCs (3%). Two of the three tumors that were suspicious (was not proven) for incomplete ablation were subjected to additional RF ablation. The remaining one enhancing lesion that was suspicious of a residual tumor on contrast-enhanced ADI was revealed to be reactive hyperemia at the 1-month follow-up CT. Therefore; the diagnostic concordance between the contrast-enhanced ADI and 1-month follow-up CT was 99%. Of the 94 ablated HCCs without residual tumors on both the contrast-enhanced ADI and 1-month follow-up CT after the initial RF ablation, five (5%) had CT findings of local tumor progression at a subsequent follow-up CT. Conclusion: Despite its limitations in predicting local tumor progression in the treated tumors, contrast-enhanced ADI is potentially useful for evaluating the early therapeutic effect of percutaneous RF ablation for HCCs.
AB - Purpose: To assess the utility of contrast-enhanced agent detection imaging (ADI) in the assessment of the therapeutic response to percutaneous radiofrequency (RF) ablation in patients with hepatocellular carcinoma (HCC). Materials and methods: Ninety patients with a total of 97 nodular HCCs (mean, 2.1 ± 1.3 cm; range, 1.0-5.0 cm) treated with percutaneous RF ablation under the ultrasound guidance were evaluated with contrast-enhanced ADI after receiving an intravenous bolus injection of a microbubble contrast agent (SH U 508A). We obtained serial contrast-enhanced ADI images during the time period from 15 to 90 s after the initiation of the bolus contrast injection. All of the patients underwent a follow-up four-phase helical CT at 1 month after RF ablation, which was then repeated at 2-4 month intervals during a period of at least 12 months. The results of the contrast-enhanced ADI were compared with those of the follow-up CT in terms of the presence or absence of residual unablated tumor and local tumor progression in the treated lesions. Results: On contrast-enhanced ADI, technical success was obtained in 94 (97%) of the 97 HCCs, while residual unablated tumors were found in three HCCs (3%). Two of the three tumors that were suspicious (was not proven) for incomplete ablation were subjected to additional RF ablation. The remaining one enhancing lesion that was suspicious of a residual tumor on contrast-enhanced ADI was revealed to be reactive hyperemia at the 1-month follow-up CT. Therefore; the diagnostic concordance between the contrast-enhanced ADI and 1-month follow-up CT was 99%. Of the 94 ablated HCCs without residual tumors on both the contrast-enhanced ADI and 1-month follow-up CT after the initial RF ablation, five (5%) had CT findings of local tumor progression at a subsequent follow-up CT. Conclusion: Despite its limitations in predicting local tumor progression in the treated tumors, contrast-enhanced ADI is potentially useful for evaluating the early therapeutic effect of percutaneous RF ablation for HCCs.
KW - Agent detection imaging
KW - Computed tomography
KW - Contrast media
KW - Liver neoplasms
KW - Radiofrequency ablation
KW - Ultrasonography
UR - http://www.scopus.com/inward/record.url?scp=24944508661&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24944508661&partnerID=8YFLogxK
U2 - 10.1016/j.ejrad.2005.03.023
DO - 10.1016/j.ejrad.2005.03.023
M3 - Article
VL - 56
SP - 66
EP - 73
JO - European Journal of Radiology
JF - European Journal of Radiology
SN - 0720-048X
IS - 1
ER -